Edwin A Alvarez, MD
Gynecological Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
- Since medical school
- 26 years
- University of California, San Diego School of Medicine, 2000
Offices
2 locations · University of California San Francisco · UCSF Medical Group Business Services
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Alvarez’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A78109 · Current
Licensed to practise in California · since 2002 · expires 2027-07-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Gynecologic Oncology
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$80,669
Medicare paid this office $80,669 for 164 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 64 | $21,516 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $7,295 | $104 |
| Return visit (30+ min) | 59 | $6,651 | $84 |
| New patient visit (60+ min) | 40 | $6,439 | $161 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 99 | $3,131 | $15 |
See all 7 services
| Long return visit (40+ min) | 64 | $21,516 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $7,295 | $104 |
| Return visit (30+ min) | 59 | $6,651 | $84 |
| New patient visit (60+ min) | 40 | $6,439 | $161 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 99 | $3,131 | $15 |
| Short return visit (20+ min) | 43 | $2,546 | $50 |
| Short return visit | 15 | $469 | $29 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Removal of the uterus | 13 | More than 87% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | – | – | 15 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
164 Original Medicare patients in 2024. Average age 71 · Women 100% · Also on Medicaid 40% · Health risk score 2.06. Above the middle of the specialty; the typical gynecological oncology clinician is at 1.53.
Conditions among them: High blood pressure 71% · Cancer 51% · Diabetes 33% · Chronic kidney disease 30% · Depression 29% · Atrial fibrillation 17% · Coronary heart disease 13% · Heart failure 13% · COPD 13% · Dementia 7% · Stroke 7%.
The office billed $520,308, Medicare allowed $102,889 and paid $80,669; for 702 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 164 | 702 | 71 | 2.06 | $520,308 | $80,669 |
| 2023 | 140 | 396 | 72 | 2.07 | $399,455 | $61,855 |
| 2022 | 138 | 411 | 71 | 1.86 | $388,812 | $61,053 |
| 2021 | 150 | 427 | 69 | 1.72 | $453,756 | $71,986 |
| 2020 | 95 | 309 | 70 | 1.84 | $265,890 | $38,233 |
| 2019 | 94 | 282 | 69 | 1.97 | $259,864 | $37,543 |
| 2018 | 80 | 191 | 72 | 2.37 | $194,275 | $28,327 |
| 2017 | 61 | 151 | 69 | 2.12 | $129,463 | $19,791 |
| 2016 | 167 | 398 | 70 | 2.12 | $241,432 | $51,127 |
| 2015 | 198 | 521 | 70 | 1.89 | $337,796 | $73,055 |
| 2014 | 162 | 422 | 70 | 1.78 | $232,832 | $54,397 |
| 2013 | 86 | 196 | 69 | 1.61 | $145,824 | $33,673 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 45 | $13,846 | $121 |
| New patient visit (60+ min) | 39 | $5,979 | $153 |
| Return visit (30+ min) | 42 | $4,254 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $3,902 | $105 |
| Short return visit (20+ min) | 47 | $2,944 | $53 |
| Short return visit | 21 | $691 | $30 |
2022: 6 services
| Long return visit (40+ min) | 46 | $12,299 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $7,865 | $90 |
| New patient visit (60+ min) | 53 | $7,854 | $148 |
| Return visit (30+ min) | 37 | $3,517 | $78 |
| Short return visit (20+ min) | 34 | $2,083 | $56 |
| Hospital discharge day management, 30 minutes or less | 14 | $1,355 | $65 |
2021: 8 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 15 | $12,359 | $824 |
| New patient visit (60+ min) | 57 | $9,933 | $174 |
| Long return visit (40+ min) | 40 | $9,805 | $132 |
| Return visit (30+ min) | 57 | $8,974 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $4,622 | $86 |
| Short return visit (20+ min) | 23 | $1,561 | $60 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $981 | $89 |
| Hospital discharge day management, 30 minutes or less | 13 | $918 | $66 |
2020: 4 services
| Return visit (30+ min) | 42 | $6,064 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $4,314 | $94 |
| Short return visit (20+ min) | 33 | $2,897 | $46 |
| New patient visit (30+ min) | 14 | $966 | $69 |
2019: 5 services
| Return visit (30+ min) | 42 | $5,951 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,112 | $93 |
| New patient visit (60+ min) | 14 | $1,966 | $140 |
| New patient visit (30+ min) | 19 | $1,291 | $68 |
| Short return visit (20+ min) | 18 | $1,012 | $46 |
2018: 3 services
| Return visit (30+ min) | 35 | $4,406 | $66 |
| New patient visit (60+ min) | 19 | $2,831 | $149 |
| Short return visit (20+ min) | 23 | $1,359 | $45 |
2017: 4 services
| New patient visit (60+ min) | 16 | $2,267 | $142 |
| Short return visit (20+ min) | 23 | $1,912 | $46 |
| Return visit (30+ min) | 18 | $1,779 | $66 |
| New patient visit (45+ min) | 11 | $1,268 | $115 |
2016: 9 services
| Return visit (30+ min) | 50 | $4,879 | $60 |
| Short return visit (20+ min) | 65 | $2,915 | $35 |
| Long return visit (40+ min) | 24 | $2,559 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,395 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $2,005 | $57 |
| New patient visit (60+ min) | 13 | $1,552 | $119 |
| New patient visit (45+ min) | 13 | $1,143 | $88 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $1,080 | $77 |
| Short return visit | 23 | $388 | $15 |
2015: 9 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 12 | $8,088 | $674 |
| New patient visit (60+ min) | 39 | $5,216 | $134 |
| Short return visit (20+ min) | 66 | $4,636 | $38 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $4,571 | $85 |
| Return visit (30+ min) | 52 | $4,457 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $3,412 | $59 |
| New patient visit (45+ min) | 16 | $1,440 | $90 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,067 | $82 |
| Short return visit | 33 | $745 | $21 |
2014: 6 services
| Return visit (30+ min) | 69 | $8,319 | $61 |
| New patient visit (60+ min) | 41 | $5,334 | $130 |
| Short return visit (20+ min) | 61 | $3,925 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,512 | $58 |
| New patient visit (45+ min) | 13 | $1,362 | $105 |
| Short return visit | 16 | $284 | $18 |
2013: 4 services
| New patient visit (60+ min) | 27 | $3,562 | $132 |
| Return visit (30+ min) | 29 | $2,148 | $58 |
| Short return visit (20+ min) | 29 | $1,601 | $39 |
| Long return visit (40+ min) | 15 | $1,408 | $83 |
Medicaid work
$40,201 in 2024
Medicaid paid $40,201 for 283 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 63 | $21,515 |
| Long return visit (40+ min) | 131 | $17,075 |
| Short return visit (20+ min) | 18 | $749 |
| Return visit (30+ min) | 14 | $629 |
| Telehealth transmission, per minute, professional services bill separately | 27 | $232 |
| Service | 30 | $0 |
| 2024 | 283 | 6 | 20 | $40,201 |
| 2023 | 210 | 6 | 16 | $31,662 |
| 2022 | 191 | 4 | 19 | $12,388 |
| 2021 | 153 | 3 | 20 | $11,705 |
| 2020 | 97 | 2 | 20 | $5,322 |
| 2019 | 201 | 2 | 20 | $20,265 |
| 2018 | 118 | 2 | 18 | $25,086 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 85 | $25,650 |
| Long return visit (40+ min) | 32 | $4,435 |
| Short return visit (20+ min) | 13 | $878 |
| Telehealth originating site facility fee | 13 | $500 |
| Telehealth transmission, per minute, professional services bill separately | 29 | $198 |
| Service | 38 | $0 |
2022
| Long return visit (40+ min) | 77 | $8,901 |
| Telehealth originating site facility fee | 50 | $1,850 |
| Return visit (30+ min) | 17 | $1,227 |
| Telehealth transmission, per minute, professional services bill separately | 47 | $410 |
2021
| Return visit (30+ min) | 112 | $8,652 |
| Long return visit (40+ min) | 13 | $1,864 |
| Telehealth originating site facility fee | 28 | $1,189 |
2020
| Return visit (30+ min) | 82 | $5,271 |
| Telehealth transmission, per minute, professional services bill separately | 15 | $51 |
2019
| Return visit (30+ min) | 170 | $10,610 |
| Clinic visit/encounter, all-inclusive | 31 | $9,654 |
2018
| Clinic visit/encounter, all-inclusive | 69 | $21,688 |
| Return visit (30+ min) | 49 | $3,399 |
Drugs they prescribed that Part D paid
$187,441
Pharmacies billed $187,441 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
95 generic and 27 brand-name prescriptions · $187,441 in drug cost · 15 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ondansetron | 12 | $61 | $3 |
Year by year
| 2024 | 122 | 39 | None | 22% | $187,441 |
| 2023 | 106 | 35 | None | None | $20,508 |
| 2022 | 124 | 39 | 0% (0) | 13% | $163,234 |
| 2021 | 163 | 38 | None | 7% | $79,998 |
| 2020 | 127 | 36 | 0% (0) | 21% | $247,804 |
| 2019 | 136 | 33 | None | None | $119,320 |
| 2018 | 112 | 27 | None | None | $117,979 |
| 2017 | 67 | 26 | None | None | $1,629 |
| 2016 | 215 | 48 | 8% (17) | 12% | $29,555 |
| 2015 | 264 | 48 | 16% (43) | None | $30,226 |
| 2014 | 221 | 47 | 12% (26) | None | $24,296 |
| 2013 | 122 | 24 | 14% (17) | None | $14,302 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Letrozole | 13 | $348 | $27 |
| Ondansetron | 12 | $112 | $9 |
2022: 2 drugs
| Ondansetron | 20 | $336 | $17 |
| Dexamethasone | 11 | $271 | $25 |
2021: 4 drugs
| Ondansetron | 20 | $361 | $18 |
| Prochlorperazine Maleate | 24 | $263 | $11 |
| Letrozole | 16 | $223 | $14 |
| Gabapentin | 12 | $115 | $10 |
2020: 3 drugs
| Lynparza | 12 | $177,391 | $14,783 |
| Megestrol Acetate | 14 | $838 | $60 |
| Ondansetron | 21 | $617 | $29 |
2019: 2 drugs
| Ondansetron | 12 | $114 | $9 |
| Prochlorperazine Maleate | 14 | $101 | $7 |
2017: 1 drug
| Gabapentin | 11 | $110 | $10 |
2016: 6 drugs
| Anastrozole | 28 | $332 | $12 |
| Duloxetine | 15 | $315 | $21 |
| Ondansetron | 20 | $180 | $9 |
| Letrozole | 12 | $163 | $14 |
| Prochlorperazine Maleate | 21 | $120 | $6 |
| Lorazepam | 13 | $61 | $5 |
2015: 7 drugs
| Hydrocodone-Acetaminophen | 25 | $621 | $25 |
| Ondansetron | 31 | $398 | $13 |
| Amitriptyline | 17 | $176 | $10 |
| Letrozole | 15 | $143 | $10 |
| Anastrozole | 16 | $131 | $8 |
| Prochlorperazine Maleate | 16 | $77 | $5 |
| Lorazepam | 16 | $60 | $4 |
2014: 6 drugs
| Megestrol Acetate | 11 | $283 | $26 |
| Ondansetron | 20 | $255 | $13 |
| Hydrocodone-Acetaminophen | 14 | $231 | $16 |
| Letrozole | 15 | $209 | $14 |
| Prochlorperazine Maleate | 18 | $99 | $5 |
| Dexamethasone | 19 | $55 | $3 |
2013: 4 drugs
| Hydrocodone-Acetaminophen | 13 | $175 | $13 |
| Lorazepam | 16 | $70 | $4 |
| Prochlorperazine Maleate | 14 | $70 | $5 |
| Dexamethasone | 15 | $48 | $3 |
Money from drug and device companies
$241 in 2024
| 2024 | 5 | 6 | None | $241 |
| 2023 | 3 | 3 | $1,900 | $1,945 |
| 2022 | 1 | 1 | $1,170 | $1,170 |
| 2021 | 3 | 3 | $6,630 | $6,651 |
| 2020 | 1 | 3 | None | $59 |
| 2019 | 3 | 6 | $1,620 | $1,805 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Intuitive Surgical | Da Vinci Surgical System | $92 | 1 payment
|
| GlaxoSmithKline | Zejula | $65 | 1 payment
|
| Ethicon US | Harmonic | $56 | 1 payment
|
| ViiV Healthcare | Dovato | $15 | 1 payment
|
| Pfizer | Tivdak | $14 | 2 payments
|
See all 6 published payments
| GlaxoSmithKline | Education · 2024-09-09 | Zejula | $65 |
| ViiV Healthcare | Meals · 2024-09-05 | Dovato | $15 |
| Intuitive Surgical | Meals · 2024-05-14 | Da Vinci Surgical System | $92 |
| Pfizer | Meals · 2024-05-08 | Tivdak | $12 |
| Pfizer | Meals · 2024-05-07 | Tivdak | $2 |
| Ethicon US | Meals · 2024-04-16 | Harmonic | $56 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $1,945
| EMD Serono Research & Development Institute | None | $1,900 | 1 payment
|
| ViiV Healthcare | Cabenuva | $30 | 1 payment
|
| Medline Industries Lp | None | $15 | 1 payment
|
2022: $1,170
| Eisai | None | $1,170 | 1 payment
|
2021: $6,651
| Eisai | Lenvima | $4,680 | 1 payment
|
| GlaxoSmithKline | Zejula | $1,950 | 1 payment
|
| Boston Scientific | Resonate | $21 | 1 payment
|
2020: $59
| Boston Scientific | Lux-Dx | $59 | 3 payments
|
2019: $1,805
| Eisai | Lenvima | $1,620 | 1 payment
|
| Merck Sharp & Dohme | None | $115 | 1 payment
|
| Intuitive Surgical | Da Vinci Surgical System | $71 | 4 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2020 | Their institution | $380,339 |
| Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2019 | Their institution | $351,920 |
| Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2021 | Their institution | $190,266 |
| Genmab U.S., Inc. · A Phase 3 Randomized, Open-Label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator'S Choice (Ic) in Patients With Platinum Resistant Ovarian Cancer · 2025 | Their institution | $73,605 |
| Genentech, Inc. · Multicenter Multi Cohort Open Label Ph2 Study of Biomarker Driven Therapies for Recurrent R Oc Pat · 2024 | Their institution | $62,535 |
| Sumitomo Pharma America, Inc. · Multicenter, Open-Label, Phase I Study of Dsp-7888 Dosing Emulsion in Patients With Advanced Malignancies · 2024 | Their institution | $52,337 |
| Genentech, Inc. · Multicenter Multi Cohort Open Label Ph2 Study of Biomarker Driven Therapies for Recurrent R Oc Pat · 2023 | Their institution | $50,000 |
| Merck Sharp & Dohme LLC · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2022 | Their institution | $46,825 |
| TRILLIUM THERAPEUTICS USA, LLC · A Phase 12 Study of Tti 622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinumresistant Ovarian Cancer · 2024 | Their institution | $36,522 |
| Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician'S Choice in Subjects With Advanced Endometrial Cancer · 2019 | Their institution | $32,492 |
| Genentech, Inc. · Multicenter Multi Cohort Open Label Ph2 Study of Biomarker Driven Therapies for Recurrent R Oc Pat · 2025 | Their institution | $31,598 |
| Genmab A/S · A Phase 2 Exploratory, Multicenter, Open-Label Trial To Determine the Safety and Preliminary Clinical Activity of Gen1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer · 2024 | Their institution | $25,622 |
| Merck Sharp & Dohme LLC · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2024 | Their institution | $4,862 |
| Merck Sharp & Dohme LLC · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2023 | Their institution | $1,712 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1710197330
- Licence
- CA A78109California A78109: Current · expires 2027-07-31
- Trained
- University of California, San Diego School of Medicine, 2000 · 26 years ago
- Group
- University of California San Francisco · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A781090
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X)
- Mailing address
- 4860 Y St, Suite 2500, Sacramento, CA, 95817
- NPI first listed
- 2007-05-23
- NPI last updated
- 2012-12-07
This is when the NPI record was last certified, not a medical board exam.